What is already known about this topic? Preliminary data suggest increased type 2 cytokines during the COVID-19 cytokine storm. However, it remains unclear how COVID-19 outcomes differ between patients with atopic dermatitis (AD) on type 2etargeting agents (dupilumab) and those treated with other systemics or topical treatments.What does this article add to our knowledge? This is the first study to directly compare the severity of COVID-19 symptoms in patients with moderate-to-severe AD on different treatments, shedding important light on the treatment of patients with AD during the pandemic and beyond.How does this study impact current management guidelines? Our results suggest that type 2 targeting with dupilumab may attenuate COVID-19 responses, supporting the safety of specific type 2etargeting agents in patients with AD during the COVID-19 pandemic, and potentially extending to other viral infections.BACKGROUND: In the SARS-CoV-2/COVID-19 pandemic, we need to understand the impact of immunomodulatory medications on COVID-19 symptom severity in patients with inflammatory diseases, including the type 2/Th2 polarized skin disease, atopic dermatitis (AD). OBJECTIVE: Because it is believed that type 1/Th1 immunity controls viral infections and that there is a Th1/Th2 counterregulation, we hypothesized that Th2 targeting with the IL-4Ra-antagonist, dupilumab, in patients with moderate-to-severe AD would rebalance the Th1/Th2 axis, potentially leading to attenuated COVID-19 symptoms. METHODS: A total of 1237 patients with moderate-to-severe AD in the Icahn School of Medicine at Mount Sinai Department of Dermatology were enrolled in a registry. Patients were screened for COVID-19-related symptoms and assigned a severity score (asymptomatic [0]-fatal [5]). Scores were compared among 3 treatment groups: dupilumab (n [ 632), other systemic treatments (n [ 107), and limited/no treatment

The incidence of cutaneous melanoma continues to rise dramatically worldwide, presenting a significant burden to the healthcare system. Despite this, there is still controversy in the guidelines regarding follow-up surveillance for patients with thin melanoma. Since there are no randomized clinical trials to support evidence-based guidelines for follow-up surveillance, dermatologic and oncologic organizations have developed their own recommendations based on expert opinion. However, these recommendations differ widely and are often vague, resulting in considerable variability in the management of early-stage melanoma among clinicians. The benefits of frequent follow-up visits are early detection of recurrent lesions, lower cost of early-stage melanoma compared to that of late-stage melanoma, decreased need for sentinel lymph node biopsy and adjuvant therapies, and the opportunity to educate patients on self-examination and sun protection. However, the high cost of screening and potential increased rates of biopsy, as well as over-imaging and overtreating, pose serious concerns about this approach. While more rigorous research is needed to resolve this controversy, currently clinicians should follow a relatively universal recommendation to tailor the follow-up regimen based on the patient's relative risk of recurrence and comfort.

Introduction: Psoriasis is a chronic inflammatory skin disease characterized by dysregulation of keratinocytes and presenting as sharply demarcated, scaly, erythematous plaques and varying levels of systemic involvement.1-3 The pathogenesis of the disease is multifactorial and includes immunologic, genetic, and environmental factors.3 Increased understanding of the involved immune-mediated inflammatory pathways has led to the development of new targeted therapies.3 This review focuses on the safety and efficacy of novel topical, oral, and injectable therapeutic options for treatment of psoriasis.Objectives: The primary objective of this study is to present safety and efficacy data on current and upcoming topical, oral, and biologic therapies for the treatment of psoriasis.Methods: Review of randomized controlled trials on the efficacy and safety of current and upcoming topical, oral, and biologic therapies via an electronic literature search using PubMed, The Cochrane Library, ClinicalTrials.gov, and data presented at AAD VMX 2021.Results: A total of 15 oral, topical or biologic therapies were included and the latest clinical trial safety and efficacy data was presented for the following therapies: